XTL Biopharmaceuticals Annual General Meeting of Shareholders Appoints Two New Members to the Board of Directors
PR Newswire - Tue Dec 30, 11:23AM CST
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"
XTL: 59.49 (+0.33), BCOM: 15.76 (unch), XTLB: 2.08 (-0.04)
XTL Biopharmaceuticals Appoints Dr. Jonathan Schapiro MD and Dr. Dobroslav Melamed to the Board of Directors to Help Lead Development of its Clinical Assets
PR Newswire - Mon Dec 08, 7:30AM CST
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"
XTL: 59.49 (+0.33), XTLB: 2.08 (-0.04)
XTL Biopharma Q3 results
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 7:21AM CST
XTLB: 2.08 (-0.04)
XTL Biopharmaceuticals Provides Financial and Operational Update For the Third Quarter of 2014
PR Newswire - Mon Dec 01, 7:00AM CST
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"
XTL: 59.49 (+0.33), XTLB: 2.08 (-0.04)
XTL Biopharmaceuticals EPS of $0
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 6:34AM CST
XTLB: 2.08 (-0.04)
Midday Gainers/ Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 11:49AM CST
FRM: 7.65 (+0.09), NEO: 4.10 (unch), AU: 12.33 (+0.36), FNHC: 29.64 (-0.29), AMS: 2.48 (+0.06), NYMX: 0.36 (-0.02), AMDA: 0.65 (+0.01), CVD: 107.08 (+0.05), GBIM: 7.85 (+0.25), RCAP: 10.28 (+0.28), KBIO: 0.45 (+0.06), COOL: 1.19 (unch), SAPE: 24.98 (-0.02), XTLB: 2.08 (-0.04), GERN: 3.03 (unch), ANIP: 62.69 (-0.43), BBLU: 1.26 (+0.09), NXTD: 2.70 (+0.04), AP: 18.27 (+0.09), ALQA: 6.14 (+0.09)
XTL Biopharmaceuticals Provides Financial and Operational Update for the Second Quarter of 2014
PR Newswire - Tue Sep 02, 11:09AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"
XTL: 59.49 (+0.33), XTLB: 2.08 (-0.04)
XTL Bio's hCDR1 Compound Highlighted in Article Reviewing Potential Candidates for the Treatment of Lupus Published in Journal of Autoimmunity
PR Newswire - Wed Jul 16, 8:18AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"
XTL: 59.49 (+0.33), XTLB: 2.08 (-0.04)
XTL Biopharmaceuticals Receives Correspondence Regarding Nasdaq Listing Requirements
PR Newswire - Thu Jun 12, 7:00AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"
XTL: 59.49 (+0.33), XTLB: 2.08 (-0.04)